
Infosys delivered a mixed quarter for Q2 FY27. Revenue grew 1.5% year-on-year in constant currency terms to ₹49,244 crore, while net profit rose 6.2% to ₹7,823 crore. Operating margin held steady at 21%, sitting right in the middle of the company's 20-22% guidance band.
But the headline that grabbed attention was the guidance cut. Management reduced its FY27 constant-currency revenue growth outlook to 1-2% from the previous 1.5-3%. This is the second consecutive revision—the original April guidance stood at 1.5-3.5%.
.
The company also flagged weakness in specific verticals. Retail and high tech sectors saw lower-than-expected discretionary spending, while client-specific project slowdowns added to the drag.
Here's the irony: Infosys is winning big deals, but it's struggling to grow revenue.
.
Yet this AI momentum isn't translating into stronger overall growth. Why?
.
Competition is intensifying, giving clients more leverage to negotiate better rates. Nomura noted that pricing pressure resulted in lower-than-expected price increases and softer volume growth in Q2. The result is a squeeze on both the top line and pricing power.
You might expect weak revenue growth to crush margins, but Infosys has managed to hold the line. Operating margin remained flat at 21% in Q2, supported by cost-efficiency measures under "Project Maximus" and favorable currency movements.
The margin walk tells the story. Headwinds of 70 basis points from post-sales customer support costs and 20 bps from acquisitions were offset by tailwinds of 40 bps from currency, 20 bps from additional working days, and 20 bps from Project Maximus.
However, brokerages like Goldman Sachs and Morgan Stanley expect margins to remain "range-bound" going forward. The logic is straightforward: cost levers like Maximus and utilization gains are largely offset by pricing deflation, wage hikes, AI investments, and acquisition dilution. Transcript
Management has flagged higher compensation costs and continued pricing pressure as second-half headwinds. With revenue growth stuck at 1-2%, there's little operating leverage to push margins toward the upper end of the 20-22% band.
The guidance cut has split Wall Street and Dalal Street. Here's how the major brokerages line up:
Nomura (Buy, ₹1,300): The Japanese brokerage sees the guidance cut as slightly better than feared. It notes that the lower end assumes further macro deterioration, while the upper end factors in improvement. Nomura still cut its FY27-28 revenue growth estimates to 1.1-2.0% from 1.2-2.8%, but maintains a bullish stance with a target implying about 12.5% upside.
Goldman Sachs (Neutral, ₹1,000): The second consecutive guidance cut points to continued weakness in revenue visibility. The revised midpoint implies modest negative organic growth when you strip out the 170 bps contribution from acquisitions. Goldman's target suggests downside from current levels.
Morgan Stanley (Equal-Weight, ₹1,075): Q2 revenue and margins missed estimates. Strong deal wins could partly offset FY28 revenue headwinds from a client exit, but recovery depends on converting those wins into revenue. Weak discretionary spending, competition, and AI pricing pressures remain concerns with no clear near-term catalyst.
Citi (Neutral, ₹1,105): Infosys is executing reasonably well despite industry challenges, but growth is expected to remain subdued. The mega deal addresses concerns about entering FY28 at a disadvantage, but cautious client spending and AI competition weigh on the outlook. Citi remains cautious on the sector.
Choice Institutional Equities (Reduce, ₹1,060): The brokerage sees Q2 results as mixed with near-term growth under pressure. Strong bookings and AI adoption offer recovery visibility, but execution, deal conversion, and margin protection are key risks. Its target is based on 13x average FY28-29 EPS.
The guidance range itself tells a story about macro uncertainty. The 1-2% band includes about 170 bps from acquisitions, meaning organic growth could range from roughly -0.7% to +0.3% depending on how the macro plays out.
The lower end assumes further macroeconomic deterioration, while the upper end assumes improvement. The fact that even the "improvement" scenario yields only 2% growth shows how far expectations have been reset.
Sector-wide challenges are amplifying company-specific issues. Cautious client spending, AI-related pricing pressures, and longer decision cycles are hitting the entire IT industry. But Infosys is also dealing with its own headwinds, including a large European manufacturing client reducing spend and the company walking away from unprofitable deals. Transcript
Here's the critical question facing investors: Will those $5.2 billion in large deals actually translate into revenue growth?
Morgan Stanley emphasized that recovery depends on converting deal wins into revenue. The risks are real. Large transformation deals ramp up gradually, not overnight. Vendor consolidation deals convert faster, but they often replace existing work rather than adding net-new revenue. Transcript
There's also the replacement risk. Finsee's analysis suggests AI services and large contracts might be replacing older work at lower prices rather than adding to top-line growth. Non-AI sales fell about 1% quarter-on-quarter, and growth from businesses owned a year ago was roughly flat to slightly negative.
The mega deal over $2 billion is expected to add over 1% to annual revenue, which could partly offset FY28 headwinds from client exits. But "partly" is the operative word. The deal needs to ramp up smoothly, and its margin profile needs to hold up in a competitive pricing environment.
Infosys faces a tricky balancing act. It's investing heavily in AI capabilities and winning large, complex transformation deals. But near-term growth visibility is clouded by macro uncertainty, pricing pressure, and the time it takes for big deals to convert into revenue.
The brokerage divide reflects different views on how this plays out. Nomura sees enough value in the deal pipeline and AI positioning to stay bullish. Goldman, Morgan Stanley, and Citi see too much near-term uncertainty to get excited. Choice Institutional Equities wants to see execution before changing its Reduce rating.
For investors, the key metrics to watch in coming quarters will be the pace of deal conversion, AI revenue growth, and whether pricing pressure shows any signs of easing. Until then, Infosys remains a stock caught between strong long-term positioning and challenging near-term realities.